2013 will be an exciting year for Array BioPharma Inc. (NASDAQ:ARRY) as it transitions into a late-stage development company. It has a diverse pipeline of drugs with up to six potential Phase III decisions over the next year. ARRY also enjoys potentially lucrative partnerships with several large pharmaceutical companies, including Amgen (NASDAQ:AMGN), Astra Zeneca (NYSE:AZN), Celgene (NASDAQ:CELG), Genentech, and Novartis (NYSE:NVS). The potential for significant milestone and royalty revenue from these partnerships is offset by the length of time before any of the drugs may reach commercialization and the inherent risks of drug development.
(click to enlarge)
Source: March 2013 Investor Presentation
ARRY currently has four drugs in...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|